Physician profile
Alan Edward Schaffer
NPI 1255310678
$1,595.63
in general payments reported to CMS, 2019-2025
10 companies · $257 in 2025
The $257 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2021: $319 · 2022: $546 · 2023: $90.00 · 2024: $163 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $420 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.75 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $677.07 | 2021-2024 | Airsupra |
| Jazz Pharmaceuticals INC. | $281.84 | 2022-2025 | |
| Amgen INC. | $125.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.92 | 2019 | |
| Novo Nordisk INC | $118.75 | 2025 | Wegovy |
| Mallinckrodt Hospital Products INC. | $108.41 | 2021 | |
| Novartis Pharmaceuticals Corporation | $82.59 | 2019 | |
| Harmony Biosciences LLC | $47.96 | 2024 | |
| Glaukos Corporation | $16.00 | 2025 | Idosetr |
| Sunovion Pharmaceuticals INC. | $13.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Schaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.